Aster Capital Management (Difc) LTD Recursion Pharmaceuticals, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $540 Billion
- Q1 2025
A detailed history of Aster Capital Management (Difc) LTD transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 2,377 shares of RXRX stock, worth $10,387. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,377
Previous 1,263
88.2%
Holding current value
$10,387
Previous $8.54 Million
109.08%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RXRX
# of Institutions
365Shares Held
286MCall Options Held
3.28MPut Options Held
3.16M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl34.8MShares$152 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.3MShares$141 Million0.0% of portfolio
-
Baillie Gifford & CO24.4MShares$107 Million0.12% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$75.6 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$64.1 Million0.27% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $789M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...